Novartis
NEWS
Under the terms of the deal, Novartis is paying TScan an upfront technology access fee and research funding totaling $30 million.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Novartis announced that, with Incyte, it is launching a Phase III clinical trial to determine if their cancer drug Jakavi (ruxolitinib) can be used to treat COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
In a statement, the FDA said “objectionable conditions were found and documented” but did not meet the threshold for regulatory action against the Swiss pharma giant.
The following is a roundup of some of this week’s non-coronavirus biopharma news.
Novartis’ Isturisa (osilodrostat) was approved for adults with Cushing’s disease who either can’t have pituitary gland surgery or who have had the surgery but still have the disease.
The two companies forged a collaboration to discover and design novel small molecule therapeutics, such as protein degraders, across various therapeutic areas
The U.S. Department of Justice charged New Jersey-based Sandoz with four counts of conspiring to rig bids and fix prices for generic drugs.
JOBS
IN THE PRESS